PURPOSE: Prostate-specific membrane antigen positron emission tomography (PSMA-PET) guided targeted biopsy has shown potential for detecting more prostate cancer (PCa) cases. However, relying exclusively on imaging may risk missing lesions, an issue that could be addressed by incorporating radiation-guided technology. Accordingly, we aimed to develop a novel PSMA radiotracer with a long half-life, [ METHODS: In this study, we synthesized the radiotracer [ RESULTS: The efficacy and specificity of [ CONCLUSIONS: Radiation-guided technology using [ TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2300072655, Registered 20 June 2023.